坚持的医疗建议
Anna Jopowicz1, Agnieszka Piechal2,3, Elżbieta Bronisz2
1Department of Rehabilitation, Eleonora Reicher National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, Poland.
Brain sciences
|March 28, 2024
概括
患者的控制不良,往往源于不坚持治疗. 这项研究发现了显著的不遵守率,并确定了影响患者遵守药物和生活方式建议的关键因素.
科学领域:
- 神经学 神经学
- 公共卫生 公共卫生
- 药理学 药理学是指药理学的学科.
背景情况:
- 不良的控制是治疗的首要挑战.
- 不遵守药物剂量,时间和生活方式的改变经常导致持续或反复的发作.
- 准确评估患者的遵从性对于有效的治疗至关重要.
研究的目的:
- 评估患者不遵守医疗建议的患病率.
- 确定影响患者遵守药物和生活方式建议的因素.
- 了解违规行为对扣押控制的影响.
主要方法:
- 一项涉及169名患者的研究,这些患者在门诊神经病学诊所接受治疗.
- 评估合规性使用患者合规性评分量表 (PRCS),临床医生评分量表 (CRS) 和定制的作者量表.
- 分析影响遵守的因素,包括类型,酒精消费,诊所访问频率,药物治疗类型和药物数量.
主要成果:
- 不合规率因规模而异:65.3% (作者规模),10% (PRCS) 和9% (CRS).
- 显著影响遵守的因素包括类型,酒精消耗,后续检查频率,药物治疗类型和处方药物的数量.
- 与标准化尺度相比,使用作者尺度时观察到更高的不合规性.
结论:
- 对治疗建议的不遵守是普遍的,多因素的.
- 类型,生活方式选择 (酒精使用) 和治疗复杂性 (药物数量,访问频率) 是患者遵守的关键决定因素.
- 针对这些因素的定制干预措施是必要的,以改善患者的控制.
更多相关视频
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.1K
05:54Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
Published on: June 13, 2016
17.2K
相关概念视频
01:24Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
288
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
288
01:08Antiepileptic Drugs: Sodium Channel Blockers
530
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
530
01:14Antiepileptic Drugs: Glutamate Antagonists
338
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
338
01:20Antiepileptic Drugs: Potassium Channel Activators
180
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
180
01:17Antiepileptic Drugs: Calcium Channel Blockers
385
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
385